Our latest white paper reveals how industrial-scale, mass spectrometry-based proteomics can help you accelerate discovery, reduce risk, and unlock new therapeutic opportunities.
Why this matters for you:
Traditional approaches often fail to address complex targets. Our platforms deliver unbiased, proteome-wide insights that enable smarter decisions and faster progression from hit to lead.
Inside the white paper:
- ScreenPep™ 2.0: High-throughput, ultra-deep proteome profiling for precise quantification of 10,000+ proteins per sample—ideal for large-scale screening.
- HT-ABPP & HT-PALMS: Identify covalent and reversible ligands directly in human cells, mapping ligandable sites across the proteome.
- Fragment-Based Innovation: Discover novel binders and E3 ligase recruiters for targeted protein degradation (TPD) and stabilization (TPS).
- Real-world case studies: Practical examples of accelerating first-in-class therapeutics.—
Your benefit:
Gain a competitive edge with scalable solutions that de-risk early discovery, expand druggable space, and enable breakthrough therapies.
Download now to learn how Evotec can help you overcome the toughest challenges in drug discovery.
Offered Free by: Evotec
See All Resources from: Evotec
